Leman

Based in Shenzhen, China and founded in 2021, Leman Biotech Co. , Ltd. , trading as Leman, operates as a drug developer, focusing on immunometabolism reprogramming and artificial intelligence for novel tumor immunotherapy. The company's founding team is from the Swiss federal Institute of Technology in Lausanne.

Leman is reaching a strategic cooperation with XtalPi Inc. It is headquartered in Shenzhen and has a clinical center in Switzerland. In March 2026, the firm closed series A funding round. The company focuses on the development, production and commercialization of novel oncology immunotherapeutic drugs and has developed the Meta 10 immunometabolism reprogramming technology.

The company develops novel metabolically enhanced tumor immunotherapy that can reverse immune cell depletion and induce stem immune memory, enabling the reactivation of terminally depleted T cells. The platforms established by the company are involved in the discovery, development and production of biomolecular drugs and novel immune cellular drugs, metabolically enhanced immune cell therapy and artificial intelligence (AI) computing-based super immunomodulator research and development. The company generates revenue by providing immuno-oncology drugs and services.. The company plans to use the series A funding to advance the Phase I clinical research of its ultra-low dose metabolically enhanced CAR-T cell drugs, accelerate the research and validation of its automated production processes, and initiate the clinical translation of metabolically enhanced cell therapies for solid tumors.